Syndax Pharmaceuticals: Q4 Earnings Insights
Syndax Pharmaceuticals: Q4 Earnings Insights
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results.
的股份Syndax制药公司(纳斯达克:SNDX)在盘后交易中持平,此前该公司公布了第四季度业绩。
Quarterly Results
季度业绩
Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).
每股收益同比增长0.00%,至0.44美元,超过预期的0.49美元。
Revenue of $380,000 unchanged by 0.00% from the same period last year, which beat the estimate of $200,000.
营收为38万美元,与去年同期持平0.00%,超过预期的20万美元。
Guidance
导向
Syndax Sees Q1 2021 R&D Expenses $25M-$30M; Sees Total Operating Expenses $30M-$35M
Syndax Pharmaceuticals Sees FY 2021 R&D Expenses $90M-$100M; Sees FY 2021 Total Operating Expenses $110M-$120M
Syndax预计2021年第一季度研发费用为2500万至3000万美元;预计总运营费用为3000万至3500万美元Syndax制药公司预计2021财年研发费用为9000万至1亿美元;预计2021财年总运营费用为1.1亿至1.2亿美元
Conference Call Details
电话会议详细信息
Date: Mar 08, 2021
日期:2021年3月8日
Time: 04:30 PM
时间:下午4时30分
ET Webcast URL: https://edge.media-server.com/mmc/p/wdaqmgg3
Recent Stock Performance
近期股市表现
52-week high: $27.85
52周高点:27.85美元
Company's 52-week low was at $6.88
该公司52周低点为6.88美元
Price action over last quarter: Up 22.96%
上季度价格走势:上涨22.96%
Company Overview
公司概述
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Syndax制药公司是一家临床阶段的生物制药公司,专注于开发多种癌症适应症的联合疗法流水线。该公司的候选产品是Eninostat,它对癌细胞和免疫调节细胞都有直接影响,以及SNDX-6352,它是一种抗CSF-1R单克隆抗体,可以增强人体对免疫治疗敏感的肿瘤的免疫反应。该集团的业务活动主要通过美国地区运作。
译文内容由第三方软件翻译。